{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:27:36Z","timestamp":1787887656856,"version":"build-2784847793"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Systemic inflammation is recognised as a critical driver of atherosclerotic cardiovascular disease (ASCVD), especially in patients with comorbid chronic kidney disease (CKD). This study aims to assess the prevalence of systemic inflammation in the ASCVD population in Spain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Outpatient electronic medical records from The Health Improvement Network (THIN\u00ae) database were used to identify patients with ASCVD and a C-reactive protein (CRP) measurement \u22651 between January 2014 and July 2023 in Spain. The proportion of patients with systemic inflammation (defined as CRP\u2009\u2265\u20092\u2005mg\/L) was estimated at the first CRP measurement (index date) and at the end of the study. The patients' characteristics, comorbidities, and drug dispensation in the prior 12 months were reported by systemic inflammation status at the index date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 15,798 patients with ASCVD were included in the study (mean age: 71.1 years; 57% men), of whom 34% had CKD. The proportion of patients with systemic inflammation at the index date was 58% (65% among CKD patients) and 56% (62% among CKD patients) at the end of the study. Patients with systemic inflammation were more frequently smokers, obese, with comorbidities, and had higher low-density lipoprotein cholesterol and triglycerides levels than patients without systemic inflammation. Overall, patients with ASCVD and systemic inflammation used statins and aspirin less frequently compared to patients without systemic inflammation, while they used antibiotics, anticoagulants, and antihypertensives more frequently.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Systemic inflammation prevalence is high among patients with ASCVD in Spain, especially among patients with comorbid CKD. Therapeutic strategies focused on targeting systemic inflammation may have beneficial effects in reducing the burden of ASCVD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1538466","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:10:32Z","timestamp":1741072232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain"],"prefix":"10.3389","volume":"12","author":[{"given":"Giancarlo","family":"Pesce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Gusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artak","family":"Khachatryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernabe","family":"Lopez-Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Vukmirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Cases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.arcmed.2015.06.006","article-title":"Global overview of the epidemiology of atherosclerotic cardiovascular disease","volume":"46","author":"Barquera","year":"2015","journal-title":"Arch Med Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global trends in atherosclerotic cardiovascular disease","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1324537","DOI":"10.3389\/fcvm.2024.1324537","article-title":"Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain","volume":"11","author":"Martinez Lopez","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B5","article-title":"GdEMd. Estrategia en Salud Cardiovascular del Sistema Nacional de Salud (ESCAV) (2022).","year":""},{"key":"B6","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"107238","DOI":"10.1016\/j.vph.2023.107238","article-title":"Targeting residual inflammatory risk: the next frontier for atherosclerosis treatment and prevention","volume":"153","author":"Ridker","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jacc.2021.12.017","article-title":"Inflammation, aging, and cardiovascular disease: JACC review topic of the week","volume":"79","author":"Liberale","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","article-title":"Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease","volume":"45","author":"Mazhar","year":"2024","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and progression of CKD: the CRIC study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/cells12121581","article-title":"The role of inflammation in CKD","volume":"12","author":"Kadatane","year":"2023","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease","volume":"18","author":"Speer","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","article-title":"Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (justification for the use of statins in prevention-an intervention trial evaluating Rosuvastatin) trial","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/jamacardio.2021.3079","article-title":"Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome","volume":"6","author":"Batra","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/HJR.0b013e328308bb8b","article-title":"C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study","volume":"15","author":"Jeppesen","year":"2008","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e007514","DOI":"10.1161\/JAHA.117.007514","article-title":"Comparison of cardiovascular risk factors for coronary heart disease and stroke type in women","volume":"7","author":"Leening","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1175174","DOI":"10.3389\/fcvm.2023.1175174","article-title":"Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis","volume":"10","author":"Liu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/ATVBAHA.112.301174","article-title":"Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community","volume":"33","author":"Schnabel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"New Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"A11398","DOI":"10.1161\/circ.146.suppl_1.11398","article-title":"Abstract 11398: prevalence and characteristics of systemic inflammation in adults with atherosclerotic cardiovascular disease and chronic kidney disease: results from the national health and nutrition examination survey","volume":"146","author":"Nanna MS","year":"2022","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"ehad655.2751","DOI":"10.1093\/eurheartj\/ehad655.2751","article-title":"Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.3390\/biomedicines11092444","article-title":"C-Reactive protein: the quintessential marker of systemic inflammation in coronary artery disease-advancing toward precision medicine","volume":"11","author":"Amezcua-Castillo","year":"2023","journal-title":"Biomedicines"},{"key":"B37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.21037\/jtd.2018.01.119","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial","volume":"10","author":"Thompson","year":"2018","journal-title":"J Thorac Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.15420\/ecr.2018.33.1","article-title":"The role of inflammation in diabetes: current concepts and future perspectives","volume":"14","author":"Tsalamandris","year":"2019","journal-title":"Eur Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.circir.2015.05.041","article-title":"Low-grade systemic inflammation and the development of metabolic diseases: from the molecular evidence to the clinical practice","volume":"83","author":"Leon-Pedroza","year":"2015","journal-title":"Cir Cir"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1021\/acschemneuro.9b00333","article-title":"Understanding the role of systemic inflammation in Alzheimer\u2019s disease","volume":"10","author":"Walker","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"796867","DOI":"10.3389\/fimmu.2021.796867","article-title":"The impact of systemic inflammation on Alzheimer\u2019s disease pathology","volume":"12","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/joa3.12473","article-title":"Role of inflammation in atrial fibrillation: a comprehensive review of current knowledge","volume":"37","author":"Nso","year":"2021","journal-title":"J Arrhythm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3899\/jrheum.110006","article-title":"Low-grade chronic inflammation and vascular damage in patients with rheumatoid arthritis: don't forget \u201cmetabolic inflammation\u201d","volume":"38","author":"Jeppesen","year":"2011","journal-title":"J Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/medicina58050641","article-title":"Chronic inflammation-A link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue","volume":"58","author":"Petrescu","year":"2022","journal-title":"Medicina"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2235042X18806986","DOI":"10.1177\/2235042X18806986","article-title":"Physiological markers and multimorbidity: a systematic review","volume":"8","author":"Ferreira","year":"2018","journal-title":"J Comorb"},{"key":"B47","doi-asserted-by":"publisher","first-page":"dju294","DOI":"10.1093\/jnci\/dju294","article-title":"Cigarette smoking and variations in systemic immune and inflammation markers","volume":"106","author":"Shiels","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI92035","article-title":"Inflammatory mechanisms linking obesity and metabolic disease","volume":"127","author":"Saltiel","year":"2017","journal-title":"J Clin Invest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/CIRCULATIONAHA.122.061010","article-title":"Low-density lipoprotein cholesterol is predominantly associated with atherosclerotic cardiovascular disease events in patients with evidence of coronary atherosclerosis: the western Denmark heart registry","volume":"147","author":"Mortensen","year":"2023","journal-title":"Circulation"},{"key":"B50","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC)","volume":"75","author":"Visseren","year":"2022","journal-title":"Rev Esp Cardiol"},{"key":"B51","article-title":"C reactive protein. [Updated 2023 Jul 10]","author":"Nehring","year":"2025","journal-title":"StatPearls"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1538466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:10:35Z","timestamp":1741072235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1538466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":51,"alternative-id":["10.3389\/fcvm.2025.1538466"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1538466","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"article-number":"1538466"}}